- Details
- Description
Packaging Size:
60t/bottle
Strength:
40mg
Composition:
Asciminib
Treatment:
Chronic myeloid leukemia，CML
Form:
Tablet
Brand:
LuciAsc
Quantity Unit:
40mg*60t/box
Manufacturer:
Lucius Pharmaceuticals (Lao) Co.,Ltd
About Asciminib
Asciminib is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Asciminib is a protein kinase inhibitor.
Chronic Myeloid Leukemia
Newly diagnosed
- Indicated in adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
- 80 mg PO daily OR 40 mg PO BID
- Continue for as long as clinical benefit is observed or until unacceptable toxicity
Previously treated
- Indicated in adults with previously treated Ph+ CML in CP
- 80 mg PO daily OR 40 mg PO BID
- Continue for as long as clinical benefit is observed or until unacceptable toxicity
With T315I mutation
- Indicated in adults with Ph+ CML in CP with T315I mutation
- 200 mg PO BID
- Continue for as long as clinical benefit is observed or until unacceptable toxicity
